Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Valneva Se ADR (NQ: VALN )

5.750 +0.100 (+1.77%)
Streaming Delayed Price Updated: 3:50 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Valneva Se ADR

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Palo Alto Networks To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Friday
Via Benzinga
Expert Ratings For Valneva
Via Benzinga
In-Depth Examination Of 6 Analyst Recommendations For Valneva
Via Benzinga
Adobe, SelectQuote, Similarweb And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
Pfizer And Valneva Partnered Lyme Disease Vaccine Shows Effectiveness As Booster Shot In Mid-Stage Study
Valneva and Pfizer released data from their Phase 2 study of the Lyme disease vaccine candidate VLA15, showing strong immune response and safety profile after a second booster dose, with seroconversion... 
Via Benzinga
The Analyst Landscape: 6 Takes On Valneva
Via Benzinga
Analyst Scoreboard: 8 Ratings For Valneva
Via Benzinga
What Analysts Are Saying About Valneva Stock
Via Benzinga
The Analyst Landscape: 6 Takes On Valneva
Via Benzinga
Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
ZIM Integrated Shipping Services Posts Upbeat Earnings, Joins fuboTV, Foghorn Therapeutics And Other Big Stocks Moving Higher On Monday
Via Benzinga
VALN Stock Earnings: Valneva Misses EPS, Misses Revenue for Q2 2024
VALN stock results show that Valneva missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
What Analysts Are Saying About Valneva Stock
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For Valneva
Via Benzinga
What Analysts Are Saying About Valneva Stock
Via Benzinga
VALN Stock Earnings: Valneva Misses Revenue for Q4 2023
VALN stock results show that Valneva missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace
3 Promising Biotech Stocks You Can Pick Up for Less Than $10
Healthcare innovations are big business. That said, biotech stocks under $10 may offer a higher ceiling thanks to their low price. 
Via InvestorPlace
Pfizer/Valneva's Vaccine Study For Tick-Borne Infection Completes Primary Vaccination Series, Plans Approval In 2026
Pfizer and Valneva announced the completion of the primary vaccination series in the Phase 3 VALOR trial for their Lyme disease vaccine, VLA15. Participants will be monitored until the end of the 2025... 
Via Benzinga
Valneva Seeks Expanded Use For Its Chikungunya Vaccine In Adolescents With Encouraging Phase 3 Data
Valneva released positive Phase 3 data for its single-shot chikungunya virus vaccine in adolescents. The vaccine is also expected to be approved for use in Brazil. 
Via Benzinga
VALN Stock Earnings: Valneva Misses EPS, Misses Revenue for Q1 2024
VALN stock results show that Valneva missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
National CineMedia Reports Upbeat Results, Joins Nordstrom, Core & Main And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were mixed, with the Dow Jones index gaining around 75 points on Tuesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Expert Ratings for Valneva
Via Benzinga
Analyst Ratings for Valneva
Via Benzinga
Analyst Ratings for Valneva
Via Benzinga
Smith & Wesson Brands Reports Upbeat Earnings, Joins America's Car-Mart, HCI Group And Other Big Stocks Moving Higher On Friday
U.S. stocks were higher, with the Dow Jones index gaining more than 100 points on Friday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Novavax’s dispute resolution and upcoming earnings call
Novavax navigates legal settlements, earnings expectations, and competition, hoping their protein-based vaccines become a global health game-changer. 
Via MarketBeat
Topics Earnings
Exposures COVID-19 Financial
Chikungunya Vaccine Maker Valneva Secures Non Dilutive Funding To Develop/Expand Its Clinical Pipeline
Valneva sells FDA Priority Review Voucher for $103 million after FDA approval of Ixchiq, the world's first licensed chikungunya vaccine. Proceeds to boost R&D projects. 
Via Benzinga
Exposures Product Safety
McDonald's, Caterpillar And 3 Stocks To Watch Heading Into Monday
With U.S. stock futures trading lower this morning on Monday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
Valneva Says Single Chikungunya Vaccine Shows Long-Lasting Antibody Response In Younger, Older Adults
Valneva SE (NASDAQ: VALN) reported antibody persistence data 24 months after vaccination with a single dose of its chikungunya vaccine IXCHIQ, further supporting the anticipated long-term durability of... 
Via Benzinga
FDA Approves World's First Mosquito-Borne Chikungunya Vaccine
The FDA approved Valneva SE's (NASDAQ: VALN) Chikungunya single-dose vaccine in individuals  
Via Benzinga
Exposures Product Safety
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.